No Increase in Risk With Dapagliflozin in Patients With Stage 4 CKD
Prespecified analysis of RCT shows reduced risk with dapagliflozin versus placebo for composite outcome that included kidney, CV events
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.